Orgenesis (ORGS) Competitors $1.04 -0.07 (-6.31%) As of 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ORGS vs. JATT, ELEV, CMMB, LGVN, CLDI, NAII, RLMD, RVPH, FNCH, and VYNEShould you be buying Orgenesis stock or one of its competitors? The main competitors of Orgenesis include JATT Acquisition (JATT), Elevation Oncology (ELEV), Chemomab Therapeutics (CMMB), Longeveron (LGVN), Calidi Biotherapeutics (CLDI), Natural Alternatives International (NAII), Relmada Therapeutics (RLMD), Reviva Pharmaceuticals (RVPH), Finch Therapeutics Group (FNCH), and VYNE Therapeutics (VYNE). These companies are all part of the "pharmaceutical products" industry. Orgenesis vs. Its Competitors JATT Acquisition Elevation Oncology Chemomab Therapeutics Longeveron Calidi Biotherapeutics Natural Alternatives International Relmada Therapeutics Reviva Pharmaceuticals Finch Therapeutics Group VYNE Therapeutics JATT Acquisition (NYSE:JATT) and Orgenesis (NASDAQ:ORGS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation and risk. Do institutionals and insiders have more ownership in JATT or ORGS? 48.0% of JATT Acquisition shares are held by institutional investors. Comparatively, 22.6% of Orgenesis shares are held by institutional investors. 20.0% of JATT Acquisition shares are held by insiders. Comparatively, 5.7% of Orgenesis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media prefer JATT or ORGS? In the previous week, JATT Acquisition's average media sentiment score of 0.00 equaled Orgenesis'average media sentiment score. Company Overall Sentiment JATT Acquisition Neutral Orgenesis Neutral Is JATT or ORGS more profitable? JATT Acquisition has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Orgenesis' return on equity of 0.00% beat JATT Acquisition's return on equity.Company Net Margins Return on Equity Return on Assets JATT AcquisitionN/A -49.58% 2.84% Orgenesis -3,827.81%N/A -130.18% Which has stronger valuation and earnings, JATT or ORGS? JATT Acquisition has higher earnings, but lower revenue than Orgenesis. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJATT AcquisitionN/AN/A$6.85MN/AN/AOrgenesis$662K7.54-$55.36MN/AN/A SummaryJATT Acquisition beats Orgenesis on 5 of the 7 factors compared between the two stocks. Get Orgenesis News Delivered to You Automatically Sign up to receive the latest news and ratings for ORGS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ORGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORGS vs. The Competition Export to ExcelMetricOrgenesisPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.99M$816.22M$5.54B$9.41BDividend YieldN/A4.84%3.75%4.03%P/E RatioN/A1.2021.0120.09Price / Sales7.5425.49433.8199.01Price / CashN/A19.5636.1658.27Price / Book-0.166.878.125.65Net Income-$55.36M-$4.17M$3.25B$257.91M7 Day Performance-2.80%0.03%0.97%2.09%1 Month Performance-36.97%2.12%7.36%11.13%1 Year PerformanceN/A2.14%31.31%18.40% Orgenesis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORGSOrgenesisN/A$1.04-6.3%N/AN/A$4.99M$662K0.00150Gap DownJATTJATT AcquisitionN/A$1.31-5.8%N/A-62.9%$22.60MN/A0.003High Trading VolumeELEVElevation Oncology2.7645 of 5 stars$0.38+0.8%$3.39+791.0%-87.0%$22.51MN/A-0.4640CMMBChemomab Therapeutics2.8243 of 5 stars$1.17+1.2%$8.50+626.5%-3.4%$22.06MN/A-1.5420Gap UpLGVNLongeveron3.3685 of 5 stars$1.42flat$8.67+510.3%-60.5%$21.20M$2.23M-0.2320Positive NewsGap UpCLDICalidi Biotherapeutics0.4785 of 5 stars$0.58-23.8%N/A-65.4%$21.03MN/A0.0038Gap DownNAIINatural Alternatives International1.3108 of 5 stars$3.40-2.6%N/A-42.1%$21.01M$125.48M-2.45290Positive NewsGap DownRLMDRelmada Therapeutics4.7501 of 5 stars$0.63+2.9%$5.00+696.8%-84.0%$20.83MN/A-0.2510RVPHReviva Pharmaceuticals3.3882 of 5 stars$0.43+9.7%$9.00+1,996.4%-66.1%$20.61MN/A-0.545Positive NewsGap UpHigh Trading VolumeFNCHFinch Therapeutics Group0.7891 of 5 stars$12.75flatN/A+756.2%$20.48MN/A-1.45190VYNEVYNE Therapeutics2.9445 of 5 stars$1.33-6.3%$6.25+369.9%-46.7%$20.23M$500K-1.3430Positive NewsHigh Trading Volume Related Companies and Tools Related Companies JATT Acquisition Alternatives Elevation Oncology Alternatives Chemomab Therapeutics Alternatives Longeveron Alternatives Calidi Biotherapeutics Alternatives Natural Alternatives International Alternatives Relmada Therapeutics Alternatives Reviva Pharmaceuticals Alternatives Finch Therapeutics Group Alternatives VYNE Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ORGS) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredFREE BUY ALERT: These 3 tiny AI stocks could surgeWe're living in unprecedented times. Most people think it's too late to get into AI right now … That the...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Orgenesis Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Orgenesis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
